ERCC1, RRM1 and BRCA1 mRNA expression levels and clinical outcome of advanced non-small cell lung cancer.
This study was to investigate whether the expressions of DNA repair genes ERCC1 (excision repair cross complementing 1), RRM1 (ribonucleotide reductase subunit M1) and BRCA1 (breast cancer 1) affected clinical outcome in patients with NSCLC. Patients with stage IIIb/IV NSCLC were given platinum-based chemotherapy. Messenger RNA expression levels of ERCC1, BRCA1 and RRM1 were determined by real-time polymerase chain reaction with TaqMan probes in the tumor. The relationship between these three genes with chemoresponse and overall survival was analyzed in this study. Eighty-five patients (median age 59, range 30-78) were enrolled into the study. Median overall survival (OS) was 13 months (range 10.8-15.2). Time to progression (TTP) was 6.1 months (range 5.5-6.7). Patients with low ERCC1 expression benefited more from a platinum-containing regimen (P=0.094). Patients with low RRM1 expression benefited more from a gemcitabine-containing regimen. Patients with high BRCA1 expression benefited more from an anti-tubulin-containing regimen (P=0.046). Partial response rate was 42.4%. A statistically significant difference in OS was seen in patients with low ERCC1 levels compared to patients with high ERCC1 ones. (16.5 vs. 10.0 months, P=0.045). A significant relationship was observed between the expression of ERCC1 and BRCA1 and TTP (6.5 vs. 5.1 months, P=0.001, 5.2 vs. 6.5, P=0.019, respectively). High expression of BRCA1 was associated with better survival in the anti-tubulin-containing regimen subgroup (8.7 vs. 13.0, P=0.035). ERCC1, RRM1 and BRCA1 are promising predictive and prognostic biomarkers in advanced non-small cell lung cancer.
Su
Chunxia
C
Department of Oncology, Pulmonary Hospital, Tongji University School of Medicine, 507# Zhengmin Road, Yangpu Region, 200433, Shanghai, China.
Zhou
Songwen
S
Zhang
Ling
L
Ren
Shengxiang
S
Xu
Jianfang
J
Zhang
Jie
J
Lv
Meijun
M
Zhang
Jie
J
Zhou
Caicun
C
D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000032:analysis*; D002289:Carcinoma, Non-Small-Cell Lung / Q000235:genetics* / Q000401:mortality / Q000473:pathology; D004268:DNA-Binding Proteins / Q000096:biosynthesis / Q000235:genetics*; D018572:Disease-Free Survival; D004720:Endonucleases / Q000096:biosynthesis / Q000235:genetics*; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D008175:Lung Neoplasms / Q000235:genetics* / Q000401:mortality / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D016016:Proportional Hazards Models; D012333:RNA, Messenger / Q000032:analysis; D060888:Real-Time Polymerase Chain Reaction; D012262:Ribonucleoside Diphosphate Reductase; D016896:Treatment Outcome; D025521:Tumor Suppressor Proteins / Q000096:biosynthesis / Q000235:genetics*; D044767:Ubiquitin-Protein Ligases / Q000096:biosynthesis / Q000235:genetics*
D014408:Biomarkers, Tumor; D004268:DNA-Binding Proteins; D012333:RNA, Messenger; D025521:Tumor Suppressor Proteins; C475286:RRM1 protein, human; D012262:Ribonucleoside Diphosphate Reductase; C111164:BRAP protein, human; D044767:Ubiquitin-Protein Ligases; C071447:ERCC1 protein, human; D004720:Endonucleases
Clin Cancer Res. 2004 Aug 1;10(15):4939-43
15297394
Clin Lung Cancer. 2008 Mar;9 Suppl 2:S76-82
21885003
Hum Mol Genet. 2007 Oct 1;16(19):2333-40
17855454
Lung Cancer. 2009 Jul;65(1):105-11
19036469
Clin Lung Cancer. 2008 Nov;9(6):331-9
19073515
N Engl J Med. 2006 Sep 7;355(10):983-91
16957145
Clin Cancer Res. 1998 May;4(5):1087-100
9607565
J Clin Oncol. 2004 May 15;22(10):1878-85
15143080
N Engl J Med. 2007 Feb 22;356(8):800-8
17314339
Lung Cancer. 2008 Jan;59(1):95-104
17889401
Ann Oncol. 2006 Apr;17(4):668-75
16407418
Lung Cancer. 2009 Jun;64(3):326-33
18977553
PLoS One. 2008;3(11):e3695
19002265
Clin Lung Cancer. 2007 May;8(6):369-75
17562237
J Clin Oncol. 2002 Nov 1;20(21):4285-91
12409326
Oncogene. 2001 Oct 4;20(45):6597-606
11641785
Lung Cancer. 2009 Apr;64(1):98-104
18823676